← Back to Search

Glucagon-like peptide-1 receptor agonist

Efficacy of Liraglutide Therapy in Patients With IPAA

Phase 2
Waitlist Available
Led By Hans Herfarth, MD, PhD
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 4 and week 6 (treatment period 1) and week 10 and week 12 (treatment period 2)

Summary

This trial tests liraglutide, a medication that may reduce bowel movements, in patients with IPAA who have not responded to other treatments. The drug works by mimicking a natural hormone to slow digestion. Liraglutide has been used to treat diabetes and obesity by slowing stomach emptying and reducing high blood sugar.

Eligible Conditions
  • Ileal Pouchitis
  • Diverticulitis
  • Pouchitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 4 and week 6 (treatment period 1) and week 10 and week 12 (treatment period 2)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 4 and week 6 (treatment period 1) and week 10 and week 12 (treatment period 2) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean % Reduction of Bowel Frequency in Percent of the Mean 7-day Bowel Frequency After 4 Weeks of Therapy on Liraglutide vs Placebo Compared to Baseline .
Secondary study objectives
Change in the 7 Day Mean Number of Day and Night Bowel Frequency at Week 4 and 6 vs Baseline on Liraglutide vs Placebo
Discontinuation of Therapy in Each Treatment Arm
Mean % Reduction of Bowel Frequency in Percent of the Mean 7-day Bowel Frequency After 6 Weeks of Therapy on Liraglutide vs Placebo Compared to Baseline.

Side effects data

From 2023 Phase 1 & 2 trial • 27 Patients • NCT04199728
23%
Nausea
15%
Constipation
8%
Shakiness, diaphoresis, and tremor
8%
Continuing opioid withdrawal
8%
Knee pain
8%
Ringing sensation
8%
Discomfort at Dexcom sensor site
8%
Overdose to illicit drug
8%
Skin irritation spots
8%
Insect bite
8%
Bruising at injection site
8%
GI/abdominal upset
8%
Fatigue
8%
Hiccups
100%
80%
60%
40%
20%
0%
Study treatment Arm
Control Group
Investigational Group

Trial Design

2Treatment groups
Experimental Treatment
Group I: Placebo then LiraglutideExperimental Treatment2 Interventions
Participants will be randomly assigned to 6-week placebo treatment. Then after a 5-day washout, treatment will continue with 6 weeks of Liraglutide.
Group II: Liraglutide then PlaceboExperimental Treatment2 Interventions
Participants will be randomly assigned to 6-week Liraglutide treatment. Then after a 5-day washout, treatment will continue with 6 weeks of placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liraglutide Pen Injector
2021
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

University of North Carolina, Chapel HillLead Sponsor
1,561 Previous Clinical Trials
4,298,733 Total Patients Enrolled
Novo Nordisk A/SIndustry Sponsor
1,557 Previous Clinical Trials
2,446,302 Total Patients Enrolled
Hans Herfarth, MD, PhDPrincipal InvestigatorUniversity of North Carolina
4 Previous Clinical Trials
296 Total Patients Enrolled

Media Library

Liraglutide Pen Injector (Glucagon-like peptide-1 receptor agonist) Clinical Trial Eligibility Overview. Trial Name: NCT04763564 — Phase 2
Ileal Pouchitis Research Study Groups: Liraglutide then Placebo, Placebo then Liraglutide
Ileal Pouchitis Clinical Trial 2023: Liraglutide Pen Injector Highlights & Side Effects. Trial Name: NCT04763564 — Phase 2
Liraglutide Pen Injector (Glucagon-like peptide-1 receptor agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04763564 — Phase 2
~2 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top